---
schema_version: "secwatch.filing_event.v1"
accession: "0001006837-26-000005"
form_type: "8-K"
ticker: "VATE"
cik: "0001006837"
company_name: "INNOVATE Corp."
filed_at: "2026-02-10T23:59:59+00:00"
generated_at: "2026-05-16T03:29:22.691729+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MediBeacon TGFR article named 2025 JASN Editors’ Choice; commercial rollout started Jan 2026

## Summary
- MediBeacon's transdermal GFR article selected as one of five 2025 Editors' Choice articles by JASN.
- TGFR System uses Lumitrace injection and transdermal sensor to measure kidney function at point of care.
- INNOVATE holds 44.7% equity interest in MediBeacon; commercialization began Jan 2026 in select academic centers.
- Initial clinical focus: heart failure monitoring, transplant evaluation, and oncology drug dosing.

## SEC filing metadata
- accession: 0001006837-26-000005
- form_type: 8-K
- ticker: VATE
- cik: 0001006837
- company_name: INNOVATE Corp.
- filed_at: 2026-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006837/000100683726000005/0001006837-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006837/000100683726000005/hchc-20260210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001006837-26-000005
- JSON: https://secwatch.observer/filing/0001006837-26-000005.json
- Plain text: https://secwatch.observer/filing/0001006837-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.